Connection
Elaine Lam to Ipilimumab
This is a "connection" page, showing publications Elaine Lam has written about Ipilimumab.
|
|
Connection Strength |
|
|
|
|
|
0.231 |
|
|
|
-
Shay R, Nicklawsky A, Gao D, Lam ET. A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2021 08; 19(4):370-370.e7.
Score: 0.187
-
Remolina-Bonilla YA, Jimenez-Franco B, Lam ET, Bourlon MT. Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab. Oncology (Williston Park). 2020 May 13; 34(5):171-174.
Score: 0.044